Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0B1SG
|
||||
Former ID |
DIB011508
|
||||
Drug Name |
BMS-813160
|
||||
Synonyms |
BMS-585059; CCR2/CCR5 chemokine antagonist (immune disorders, cardiovascular disorders), BMS; CCR2/CCR5 dual antagonist (cardiovascular disease), Bristol-Myers Squibb; CCR2/CCR5 dual antagonist (immunology), Bristol-Myers Squibb
|
||||
Indication | Diabetic nephropathy [ICD9: 250.4; ICD10:E11.21] | Phase 2 | [524165] | ||
Company |
Bristol-myers squibb
|
||||
Structure |
Download2D MOL |
||||
Canonical SMILES |
CC(C)(N[C@H]1C[C@H]([C@@H](N2CC[C@@H](C2=O)Nc2ncnc3cc(C<br />(C)(C)C)nn23)CC1)NC(=O)C)C
|
||||
Target and Pathway | |||||
Target(s) | C-C chemokine receptor type 2 | Target Info | Modulator | [531630] | |
C-C chemokinereceptor type 5 | Target Info | Modulator | [531630] | ||
Pathway Interaction Database | IL12-mediated signaling events | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.